No Clinically Significant Interaction Between Famotidine and Metoprolol
Famotidine (Pepcid) does not have a clinically significant drug interaction with metoprolol and can be safely used together. This combination is commonly prescribed without dose adjustments or special monitoring requirements.
Pharmacologic Basis for Safety
The lack of interaction is explained by their distinct metabolic pathways:
Famotidine Metabolism
- Does not bind to the cytochrome P-450 system 1
- Hepatic metabolism accounts for only 50-80% of elimination
- No inhibition of CYP2D6, the primary enzyme metabolizing metoprolol
- Famotidine and nizatidine specifically have low potential to interact with other medications through cytochrome pathways 1
Metoprolol Metabolism
- Primarily metabolized by CYP2D6 2
- CYP2D6 poor metabolizers experience greater metoprolol exposure and more pronounced heart rate lowering 2
- Drugs that inhibit CYP2D6 (like certain tyrosine kinase inhibitors) can increase metoprolol levels by 23-35% 3
Important Contrast: Cimetidine vs. Famotidine
Critical distinction: While cimetidine (another H2-blocker) does inhibit multiple CYP enzymes including CYP2D6, famotidine does not share this property 1. This makes famotidine the preferred H2-receptor antagonist when prescribing with metoprolol or other CYP-metabolized medications.
Clinical Monitoring Considerations
While no interaction exists, monitor for:
- Bradycardia - Both medications can independently affect heart rate in specific contexts (metoprolol directly; famotidine rarely reported) 4, 5
- Hypotension - Metoprolol's expected effect 4
- Standard adverse effects of each medication independently
Practical Application
- No dose adjustment needed for either medication
- No special timing requirements between doses
- Continue standard monitoring for metoprolol therapy (heart rate, blood pressure)
- This combination is routinely used in patients with cardiovascular disease requiring acid suppression 6
The recent pharmacokinetic study 7 specifically examined this combination in rats, further confirming the ability to safely co-administer these medications while maintaining predictable pharmacokinetic profiles for both drugs.